AEF0117 has an open FDA’s IND and will enter phase IIb in the United States in 2021.
AEF0117 is a new molecular entity (NME) developed by Aelis Farma for the treatment of cannabis addiction, cannabis-induced Psychosis and Toxicity.
AEF0117 major characteristics:
Very high potency in inhibiting the effects of cannabis' active ingredient THC in several animal species including non-human primates without side effects on normal behavior.
Very favorable ADMET profile, with good oral absorption, brain access, long half-life and no toxic or adverse effects identified (Therapeutic index >14 000).
Excellent safety profile and PK characteristics in healthy volunteers and cannabis addicts.
The clinical development of AEF0117 is supported by the NIH (NIDA).